Pharmidex are delighted to be one of sixteen partners in an EU Horizon 2020 grant - HeatNMof
April 12, 2022

HeatNMof is a heating-triggered drug release from nanometric metal-organic framework composites

The Initial Training Network HeatNMof aims to develop high quality training opportunities for 12 early-stage-researchers (ESRs) in the area of materials science, advanced characterization and biomedicine.


HeatNMof is training the next generation of materials scientists in nanomedicine to exploit heat-triggered release for delivery of anti-tumour drugs. The network is focusing on one of the most promising classes of nanocomposite carriers, inorganic nanoparticles (iNPs) associated to nanoscaled metal organic frameworks (nanoMOFs).


The successful development of this project, involving seven academic, three industrial partners, six partner organisations (5 universities and 1 company), will contribute to the improvement of the highly societal relevant cancer therapy..


Partners: Fundación IMDEA Energía (Coordinator), Universidad de Santiago de Compostela; Centre National de la Recherche Scientifique; Universiteit Antwerpen; Immaterial Labs Ltd; Institut National des Sciences Appliquees de Toulouse; Universitaet Hamburg; Fondazione Istituto Italiano di Tecnologia.; Nanoscale Biomagnetics SL; Isern Patentes Y Marcas M SL.


- Partner Organisations: Universidad Rey Juan Carlos; Universidad de Zaragoza, University of Cambridge; Universite de Nantes; Universita Degli Studi di Genova; Pharmidex.


Funding Institution/Program: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skล‚odowska-Curie grant agreement Nº 860942.


Call: H2020-MSCA-ITN-2019 (ETN)


https://www.energy.imdea.org/research/projects/heatnmof

April 24, 2025
Pharmidex is proud to be exhibiting at the 36th BMCS Spring Symposium on Medicinal Chemistry, taking place today at the beautiful Fielder centre in Hatfield! ๐Ÿ›๏ธโœจ We're excited to be part of this key gathering of thought leaders in drug discovery and development, sharing insights, connecting with fellow innovators, and shaping the future of medicinal chemistry. Our very own J anette Dalay Robertson is on-site and would be delighted to meet with attendees. Come say hello! She’s eager to discuss collaboration opportunities and explore how together we can accelerate breakthroughs in drug discovery and preclinical development. ๐Ÿ’ฌ Let’s connect, innovate, and advance science, one molecule at a time.
April 22, 2025
This annual symposium is a key event in the medicinal chemistry calendar, bringing together researchers and industry professionals to discuss cutting-edge advances in drug discovery. Our team will be available to discuss how Pharmidex’s integrated services can support the development of novel therapeutics from early discovery through to candidate selection. ๐Ÿ“ Location: Hatfield, UK ๐Ÿ“… Date: 24th April 2025 ๐Ÿ”— www.pharmidex.com, https://lnkd.in/eZdCsd4M We look forward to engaging with the scientific community and exploring new opportunities for collaboration. Visit our stand or contact [email protected]. See you there!
March 21, 2025
We’re pleased to announce that Janette Dalay Robertson , our Business Development Manager, and Ian Knowles , our Head of Respiratory, will be attending the 2nd SMR Molecular Glues Meeting on Friday, 21st March 2025 at GSK, Stevenage. This event is a fantastic opportunity to engage with fellow scientists, innovators, and industry leaders in the field of molecular glues. Janette and Ian are eager to connect, share insights, and explore new collaborations to advance drug discovery and development. If you’re attending, don’t hesitate to reach out – they would love to meet and discuss how Pharmidex can support your research and development goals! ๐Ÿ”— More about the event: https://lnkd.in/d6yiTkUi
More Posts